Event
Novel Applications/Methods of Mass Spectrometry (MS) in Drug and Biologic R&D
Tuesday, December 3, 2013
2:00 p.m.-3:00 p.m.
FDA WO Campus, Bldg. 2 room 2047E
Ann Anonsen
aanonsen@umd.edu
View Recorded Presentation and video.
FDA Regulatory Science Lecture: "Novel Applications/Methods of Mass Spectrometry (MS) in Drug and Biologic R&D."
by David Goodlett, Professor and Isaac E. Emerson, Chair of Pharmaceutical Sciences, University of Maryland School of Pharmacy, Baltimore Maryland.
Abstract:
The presentation will have three phases:
1) a review of the new UMB mass spectrometry (MS) facility and our capabilities;
2) the development of a surface acoustic wave nebulization (SAWN) for biomedical MS analysis; and
3) a novel method for phenotyping bacteria including the ability to detect antibiotic resistance.
The newly re-developed UMB MS facility has a number of faculty associated with it who focus on various uses of MS in the biomedical sciences. Specifically, we conduct the following kinds of MS-based research: general bottom-up and clinical proteomics, top-down protein sequencing, tissue imaging MS, protein structure analysis by chemical crosslinking and hydrogen deuterium exchange, metabolomics and targeted small molecule quantitative analysis and metal ion analysis.
Brief Bio:
David R Goodlett is currently the Issac E. Emerson Endowed Professor of Pharmaceutical Sciences at the University of Maryland School of Pharmacy where he is also Director of the University's mass spectrometry center. In 2012 he began a four year tenure as a Finland Distinguished Professor at the University of Turku. From 2004-2012 he was Professor of Medicinal Chemistry at the University of Washington where he was also Director of the School of Pharmacy mass spectrometry facility. His research includes hypothesis generating, discovery based efforts in protein and lipid A structure-function relationships in infectious organisms, proteomics technology development and informatics. Prior to his nine year term at the University of Washington, he was Director of the Institute for Systems Biology's Proteomics laboratory (2000-2003). After postdoctoral work with Richard D. Smith at Pacific Northwest National Laboratory (1991-1993), he spent five years in the pharmaceutical industry and prior to that received his Ph.D. in 1991 with Richard B. van Breemen at North Carolina State University. Originally, he was trained as a chemist at Auburn University with John Aull, Harlow Daron and Frank Bartol in biochemistry and reproductive biology.
